WO2001098174A1 - Container for medicament powder - Google Patents
Container for medicament powder Download PDFInfo
- Publication number
- WO2001098174A1 WO2001098174A1 PCT/EP2001/006303 EP0106303W WO0198174A1 WO 2001098174 A1 WO2001098174 A1 WO 2001098174A1 EP 0106303 W EP0106303 W EP 0106303W WO 0198174 A1 WO0198174 A1 WO 0198174A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medicament
- container
- desiccant
- package
- container according
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 150
- 239000000843 powder Substances 0.000 title claims abstract description 54
- 239000002274 desiccant Substances 0.000 claims abstract description 92
- 239000000463 material Substances 0.000 claims abstract description 86
- 238000000034 method Methods 0.000 claims abstract description 12
- 238000004891 communication Methods 0.000 claims abstract description 6
- 239000010410 layer Substances 0.000 claims description 28
- 238000007789 sealing Methods 0.000 claims description 22
- 238000012546 transfer Methods 0.000 claims description 16
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 14
- 239000004927 clay Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000011888 foil Substances 0.000 claims description 13
- 229910052751 metal Inorganic materials 0.000 claims description 12
- 239000002184 metal Substances 0.000 claims description 12
- 229920003023 plastic Polymers 0.000 claims description 12
- 239000004033 plastic Substances 0.000 claims description 12
- 238000003860 storage Methods 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000011241 protective layer Substances 0.000 claims description 10
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical group C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 8
- 229920000554 ionomer Polymers 0.000 claims description 8
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 7
- 229910001570 bauxite Inorganic materials 0.000 claims description 7
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical class O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 7
- 239000001175 calcium sulphate Substances 0.000 claims description 7
- 235000011132 calcium sulphate Nutrition 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 239000002808 molecular sieve Substances 0.000 claims description 7
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 7
- 238000003466 welding Methods 0.000 claims description 7
- 239000010457 zeolite Substances 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 229910021536 Zeolite Inorganic materials 0.000 claims description 6
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 6
- 239000005022 packaging material Substances 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- 229910052782 aluminium Inorganic materials 0.000 claims description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 5
- 229960000289 fluticasone propionate Drugs 0.000 claims description 5
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 5
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 4
- 239000004411 aluminium Substances 0.000 claims description 4
- 239000012057 packaged powder Substances 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 229920006267 polyester film Polymers 0.000 claims description 3
- 229960005018 salmeterol xinafoate Drugs 0.000 claims description 3
- 239000011135 tin Substances 0.000 claims description 3
- 229910052718 tin Inorganic materials 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- -1 polyethylene Polymers 0.000 description 25
- 239000002585 base Substances 0.000 description 23
- 229940112141 dry powder inhaler Drugs 0.000 description 14
- 229920001169 thermoplastic Polymers 0.000 description 11
- 239000004416 thermosoftening plastic Substances 0.000 description 11
- 239000011358 absorbing material Substances 0.000 description 10
- 239000002650 laminated plastic Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229960004017 salmeterol Drugs 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000013618 particulate matter Substances 0.000 description 4
- 239000012466 permeate Substances 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920000098 polyolefin Polymers 0.000 description 4
- 229960002052 salbutamol Drugs 0.000 description 4
- 229910021653 sulphate ion Inorganic materials 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 229950000339 xinafoate Drugs 0.000 description 4
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 229960004436 budesonide Drugs 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000005021 flexible packaging material Substances 0.000 description 3
- 229960002848 formoterol Drugs 0.000 description 3
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920000690 Tyvek Polymers 0.000 description 2
- 239000004775 Tyvek Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000005030 aluminium foil Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940092705 beclomethasone Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 229920002313 fluoropolymer Polymers 0.000 description 2
- 239000004811 fluoropolymer Substances 0.000 description 2
- 229960002714 fluticasone Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000003475 lamination Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- PZWQOGNTADJZGH-SNAWJCMRSA-N (2e)-2-methylpenta-2,4-dienoic acid Chemical compound OC(=O)C(/C)=C/C=C PZWQOGNTADJZGH-SNAWJCMRSA-N 0.000 description 1
- UBLVUWUKNHKCJJ-ZSCHJXSPSA-N (2s)-2,6-diaminohexanoic acid;1,3-dimethyl-7h-purine-2,6-dione Chemical compound NCCCC[C@H](N)C(O)=O.O=C1N(C)C(=O)N(C)C2=C1NC=N2 UBLVUWUKNHKCJJ-ZSCHJXSPSA-N 0.000 description 1
- RZMCXMNNXGCFQG-DQEYMECFSA-N (2s)-3-[4-(4-carbamoylpiperidine-1-carbonyl)oxyphenyl]-2-[[(2s)-4-methyl-2-[[2-(2-methylphenoxy)acetyl]amino]pentanoyl]amino]propanoic acid Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(OC(=O)N2CCC(CC2)C(N)=O)=CC=1)C(O)=O)C(=O)COC1=CC=CC=C1C RZMCXMNNXGCFQG-DQEYMECFSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000011111 cardboard Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960003821 choline theophyllinate Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 239000012611 container material Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940109248 cromoglycate Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229920006242 ethylene acrylic acid copolymer Polymers 0.000 description 1
- 229920005648 ethylene methacrylic acid copolymer Polymers 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- MSKQYWJTFPOQAV-UHFFFAOYSA-N fluoroethene;prop-1-ene Chemical group CC=C.FC=C MSKQYWJTFPOQAV-UHFFFAOYSA-N 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 229960001268 isoetarine Drugs 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 229960001869 methapyrilene Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000011087 paperboard Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- 229950004432 rofleponide Drugs 0.000 description 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001771 vacuum deposition Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
- B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0043—Non-destructive separation of the package, e.g. peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0051—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0053—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type or way of disposal
- A61M15/0055—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type or way of disposal the used dosages being coiled
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/062—Desiccants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2209/00—Ancillary equipment
- A61M2209/06—Packaging for specific medical equipment
Definitions
- the present invention relates to containers and dispensers for medicament powders.
- the invention relates to dry powder inhalation dispensers and components thereof which substantially alleviate or reduce moisture build-up therein.
- the invention also relates to a method for reducing moisture ingress inside a dry powder inhaler.
- Medicaments for treating respiratory disorders are frequently administered as dry powder formulations through the mouth and nose.
- Dry powder medicament dispensers such as inhalers, are used in the administration of these drugs, inhalation by the patient resulting in uptake of a specified dosage of medicament through the nose or mouth.
- the drug may be stored as a dry powder within a reservoir in the body of the inhaler, a metering chamber being utilised to administer a specified dose of medicament.
- more sophisticated medicament dispensers employ medicament carriers, such as individual capsules or blister packs/strips containing defined doses of powdered drug.
- Another problem can be microbial contamination, which is often assisted by the undesirable presence of excess moisture.
- a desiccant in the body of the inhaler or the walls of the medicament carrier can significantly improve the aforementioned problems. Furthermore, storage of the inhaler or medicament carrier within a sealed package incorporating a desiccant, can markedly reduce moisture ingress.
- control may be achieved by either suitable choice of container materials or by enclosure of the container or a dispenser including the container in a suitable package.
- the control need not absolutely prevent moisture transfer. Indeed, the Applicants have found that under certain conditions a limited degree of moisture transfer can be desirable.
- WO 99/32180 teaches the inclusion of moisture permeable chambers containing desiccants within a blister pack.
- US patent 5,740,793 discloses the inclusion of a desiccant cartridge within an inhaler or the medicament carrier cassette.
- US patent 5,394,868 describes a chamber within a powder inhaler for holding a desiccating substance. The use of desiccant filters within medicament dispensers is described in US patents 5,687,746 and 5,775,320, and PCT patent application no. WO 89/ 01348. Summary of Invention
- a container for a medicament powder formed from a material comprising a desiccant.
- the container is suitable for containing a measured dose of medicament.
- Packs in blister pack form for the containment of a unit dose medicaments are envisaged, as are packs containing multiple unit dose blisters arranged sequentially or otherwise, such as in series form.
- a particular multi-unit dose arrangement comprises an elongate strip having multiple blisters arranged in series thereon.
- the container is a reservoir for dry powder medicament.
- Metering means are provided to enable metering of dose from the reservoir and transport of that dose to a delivery position.
- the container is a medicament dispenser comprising a body defining a reservoir for medicament in powder form, and an outlet in communication with said reservoir for release of the medicament.
- the device is an inhaler and the outlet is one through which a user can inhale.
- the container is in the form of a reloadable cartridge comprising a medicament pack (e.g. in multi-unit dose blister form or reservoir form).
- a medicament pack e.g. in multi-unit dose blister form or reservoir form.
- the cartridge is shaped and sized for receipt by a medicament delivery device (e.g. an inhaler device).
- the container is a medicament dispenser comprising a body defining a chamber for receipt of a medicament carrier, and an outlet in communication with said chamber for release of the medicament.
- the device is an inhaler and the outlet is one through which the user can inhale.
- the body consists of the material comprising the desiccant.
- the body comprises the material comprising the desiccant.
- the material comprising the desiccant coats the body e.g. part or whole of the inside of the body.
- the material comprising the desiccant is impregnated throughout the body.
- the material comprising the desiccant lines the body (e.g. the interior of the body which contacts the medicament powder in use).
- the desiccant comprising material may be located around a seal for sealing the reservoir or medicament carrier optionally the seal (e.g. in the form of a sealing ring) may itself comprise or consist of a desiccant.
- the container is a medicament carrier.
- the medicament carrier is a capsule comprising a wall enclosing the medicament.
- the medicament carrier is a blister pack comprising a base sheet and a lid.
- the medicament carrier comprises a material comprising a desiccant.
- the material comprising the desiccant coats the wall, or the base sheet, or the lid of the medicament carrier.
- the material comprising the desiccant impregnates the wall, or base sheet, or lid of the medicament carrier.
- the material comprising the desiccant lines the wall, or base sheet, or lid of the medicament carrier.
- the material comprising the desiccant is moulded into the wall, or base sheet, or lid of the medicament carrier.
- a well containing desiccant surrounds individual pockets in the blister packs.
- the blister pack comprises a laminate comprising a desiccant.
- the laminate comprises material selected from the group consisting of metal foil, organic polymeric material and paper.
- metal foils include aluminium or tin foil having a thickness of from 5 to 100 ⁇ m, preferably from 10 to 50 ⁇ m, such as 20 to 30 ⁇ m.
- Suitable organic polymeric materials include polyethylene, polypropylene, polyvinyl chloride and polyethylene terephthalate.
- the base sheet and lid comprise different materials.
- the material comprising the desiccant is an organic polymeric plastic having particular characteristics e.g. a thermoplastic.
- the organic polymeric plastic is a polyamide.
- the desiccant is selected from the group consisting of silica gel, zeolite, alumina, bauxite, anhydrous calcium sulphate, activated bentonite clay, water- absorbing clay, molecular sieve and any mixtures thereof.
- the container additionally comprises a medicament in dry powder form.
- the medicament is suitable for the treatment of respiratory disorders.
- the medicament is salmeterol xinafoate, fluticasone propionate or a combination thereof.
- a package for storage of a container for a medicament powder formed from a material capable of controlling the ingress of moisture thereto or egress or moisture therefrom.
- the material is impermeable to moisture.
- the material controls the ingress or egress of moisture such that the ambient moisture content within the package is essentially constant, such as varying by no more than ⁇ 20%, preferably by less than ⁇ 10%.
- Ambient moisture content may for example be measured by Relative Humidity within the package.
- the preferred absolute level of moisture content will vary from medicament to medicament but may be readily determined through laboratory testing.
- the material enables moisture transfer in one way only i.e. ingress only or egress only. In another aspect, the material enables moisture transfer to either a set minimum /maximum moisture content within the package or within a set minimum / maximum moisture transfer rate.
- the material is also capable of controlling the flow of other gaseous or vapour form species.
- Tyvek (trade name) is a suitable material.
- the package is wrappable and sealable around the container to form an enclosed volume in which the container is disposed, the package being impermeable to water vapour, thereby substantially reducing ingress of water vapour and particulate matter into said enclosed volume.
- the package additionally comprises a desiccant within the enclosed volume.
- the desiccant is selected from the group consisting of silica gel, zeolite, alumina, bauxite, anhydrous calcium sulphate, activated bentonite clay, water- absorbing clay, molecular sieve and any mixtures thereof.
- the package includes at least one heat sealable layer and at least one layer of a metal foil.
- the metal comprising said metal foil is selected from the group consisting of aluminium, tin, iron, zinc and magnesium.
- the package includes protective layers located on the outside of the package.
- the protective layer comprises a polyester film and the heat sealable layer comprises an ionomer film.
- a method of storing a container for a medicament powder comprising providing a packaging material which is capable of controlling the flow of water vapour; filling a container with a medicament powder; wrapping said container with said package material to form an enclosed volume in which said container is disposed therein; and sealing the package.
- the method additionally comprises providing a desiccant within the enclosed volume.
- the sealing comprises heat sealing said packaging material.
- the seal is formed by ultrasonic welding, heat stamping, adhesive or laser welding methods.
- a packaged container comprising a container containing a medicament powder; and an overwrap package enclosing the container and a desiccant; wherein the container and the desiccant are sealable within the overwrap.
- the overwrap comprises a desiccant material and/or is lined, coated or impregnated with a desiccant material.
- the overwrap package may be in the form of a shrink wrap or of a loose wrap e.g. in sachet form. Any spare volume within the overwrap may be evacuated or an inert gas such as nitrogen deliberately inserted.
- a packaged powder medicament dispenser (or reloadable cartridge therefor as described supra) comprising a medicament dispenser for a medicament powder; and an overwrap package enclosing the medicament dispenser, wherein the medicament dispenser are sealable within the overwrap.
- the overwrap package may comprise desiccant, and or the package may have desiccant contained therewithin.
- the medicament dispenser may comprise a powder reservoir or a medicament carrier for containment of medicament.
- overwrap comprises desiccant it may be impregnated or otherwise blended with material or added as a coating or a liner.
- the body of said medicament dispenser also comprises a desiccant.
- the desiccant is selected from the group consisting of silica gel, zeolite, alumina, bauxite, anhydrous calcium sulphate, activated bentonite clay, water- absorbing clay, molecular sieve, zinc chloride, and any mixtures thereof.
- a container for a medicament powder formed. from a material capable of controlling the ingress of moisture thereto or egress or moisture therefrom.
- the material is impermeable to moisture.
- the material controls the ingress or egress of moisture such that the ambient moisture content within the package is essentially constant, such as varying by no more than ⁇ 20%, preferably by less than ⁇ 10%.
- the material enables moisture transfer in one way only i.e. ingress only or egress only.
- the material enables moisture transfer to either a set minimum /maximum moisture content within the package or within a set minimum / maximum moisture transfer rate.
- the material is also capable of controlling the flow of other gaseous or vapour form species.
- the medicament container or overwrap therefor or any part of a medicament dispenser for use therewith is comprised of a material having desiccant blended or otherwise loaded or impregnated therein. Suitable materials are described in PCT Application Nos. WO99/62697 and WO/00/17258 in the name of Capitol Speciality Plastics Inc.
- Suitable materials comprise a thermoplastic/desiccant blend.
- thermoplastics include polyolefin, polyethylene, polycarbonate, polyamide, ethylene- vinyl acetate copolymer, ethylene-methacrylate copolymer, polyvinyl chloride, polystyrene, polyester, polyester amide, polyacrylic ester, and polyvinylidene chloride, acrylic, polyurethane, polyacetal, and polycarbonate.
- thermoplastics include polyolefin, polyethylene, polycarbonate, polyamide, ethylene- vinyl acetate copolymer, ethylene-methacrylate copolymer, polyvinyl chloride, polystyrene, polyester, polyester amide, polyacrylic ester, and polyvinylidene chloride, acrylic, polyurethane, polyacetal, and polycarbonate.
- the concentration of desiccant entrained (e.g. mixed or blended) within the thermoplastic may exceed seventy-five percent (75%) to not greater than eighty percent (80%) by weight, so that about seventy-five percent (75%) may extend to eighty percent (80%) by weight.
- the desiccant concentration will fall within a range of forty to seventy-five percent (40-75%) desiccant to thermoplastic, by weight. This concentration is considered to be a high concentration for most thermoplastics.
- the maximum desiccant bearable concentrations will vary among the various types of thermoplastics due to their differing characteristics.
- the maximum concentration of desiccant will be about seventy-five percent (75%) by weight.
- the performance of the material degenerates to unacceptable levels.
- about forty percent (40%) could extend to as low as thirty percent (30%) where the limits of a viable product are reached.
- Figure 1 shows a medicament carrier in the form of a capsule according to the present invention.
- Figure 2a is a cross-sectional side elevation of a single medicament blister strip impregnated with a desiccant according to the present invention.
- Figure 2b is a top perspective of a medicament blister strip illustrated in Figure 2a.
- Figure 3a is a cross-sectional side elevation of a single medicament blister having a laminate comprising a desiccant according to the present invention.
- Figure 3b is a top perspective of a medicament blister strip illustrated in Figure 3a.
- Figure 4a is a cross-sectional side elevation of a single medicament blister having a ring containing a desiccant impregnated into the laminate surrounding the blister pocket.
- Figure 4b is a top perspective of the medicament blister shown in Figure 4a.
- Figure 5 shows a cross-sectional dry powder inhaler comprising a powder reservoir according the present invention.
- Figure 6 shows a cross-sectional dry powder inhaler comprising a medicament carrier according to the present invention.
- Figure 7 is a top perspective of a package for storing a dry powder inhaler according to the present invention.
- Figure 8 is a side perspective of the package of Figure 7.
- Figure 9 is a cut-away bottom perspective of the package for storing a dry powder inhaler according to the present invention.
- Figure 10 is a cross-sectional view of the package for storing a dry powder inhaler according to the present invention.
- the medicament carrier in Figure 1 is in the form of a capsule 1 comprising a wall 2 enclosing medicament powder 5.
- the wall 2 comprises a desiccant 3 which reduces or otherwise controls moisture ingress into the capsule 1 during storage and/or when in situ within the body of the inhaler (not shown).
- Medicament powder 5 is released on piercing the wall 2 of capsule 1 and may be inhaled by a patient.
- Figure 2a shows a sectional side-elevation of a single blister strip 106 comprising a pocket 107, containing dry powder 105, base 110 and lid comprising laminates 114, 115.
- the lid is composed of a metallic foil laminate 114 bound to a plastic laminate 115.
- the lid 114, 115 is hermetically sealed to base 110 by appropriate means (e.g. adhesion, welding).
- Base 110 comprises an organic polymeric plastic impregnated with desiccant 103. In use, the desiccant absorbs any moisture which permeates through the lid 114, 115 and base 110, maintaining the powder 105 in a dry condition until the lid 114, 115 is removed from the base 110.
- FIG. 2b A top perspective of the blister strip 106 showing pockets 107 is illustrated in Figure 2b.
- Laminated lid 114, 115 is sealed to base 110 which is impregnated with desiccant 103.
- Figure 3a shows a cross-sectional elevation of a different single blister strip 206 according to the invention.
- the blister strip 206 is composed of several laminated sheets, the lid .being formed from metallic foil 214 and plastic laminate 215 while the base comprises plastic laminates 210 and 211.
- the plastic laminate 211 comprises a desiccant material 203 for absorbing any moisture which permeates through laminated sheets 214, 215 and 210, thereby reducing ingress into medicament powder 205 within pocket 207.
- Figure 3b is a top perspective of a blister strip 206 showing several blisters as described in Figure 3a.
- Metallic foil 214 and plastic laminate 215 form a lid which is hermetically sealed, by appropriate adhesive or welding means, to the base of strip 206.
- the base comprises plastic laminates 210 and 211 , laminate 211 being disposed on the internal surface of pocket 207 and comprising a desiccant.
- FIG 4a shows a cross-sectional elevation of yet another single blister strip 306 according to the invention.
- Metallic foil 314 and plastic laminate 315 form a lid for base 310 which are hermetically sealed together to reduce moisture ingress into pocket 307 containing medicament powder 305.
- the circumference of pocket 307 is surrounded by a ring 319, within base 310, comprising desiccant 303 which absorbs moisture which permeates into the blister, particularly between lid sheet 315 and base sheet 310.
- FIG. 4b A plan perspective of the single blister strip 314 shown in Figure 4a is illustrated in Figure 4b.
- the ring 319 of material comprising desiccant 303 surrounds pocket 307 thereby absorbing any moisture which permeates into the pocket 307 through foil 314 and laminates 315 and/or base sheet 310, together with moisture ingress between lid and base sheets 315, 310.
- FIG. 5 shows a sectional view of a dry powder inhaler 420 according to the present invention.
- the inhaler 420 comprises a body 421 which defines a reservoir 423 and a reservoir cover 424.
- the reservoir contains a supply of medicament in dry powder form 405.
- the walls 423 of the reservoir, defined by the body 421 are comprised of a desiccant material 403.
- Base 425 and body 421 define an aperture 430 through which powder 405 can pass from the reservoir to the dosing member 432.
- Powder 405 is guided by the walls 423 of the reservoir, which form a hopper, to the dosing member 432.
- Extending laterally from the lower end of the main body 421 is mouthpiece 435, through which the patient inhales via passage 433.
- a desiccant comprising material may be located within the walls of passage 433 and/or a ring of same material around the metering valve (not shown) which controls the flow of medicament into passage 433.
- FIG. 6 shows a simplified cross-sectional plan view of a dry powder inhaler comprising a medicament carrier according to the present invention.
- the inhaler 540 dispenses unit doses of medicament powder from a medicament blister strip 506.
- the inhaler is comprised of an outer casing 544 enclosing a medicament strip 506 within body 521.
- the medicament strip may be, for example, any of those described in Figures 2a to 4b above.
- the internal walls of body 521 are comprised of a desiccant material (not shown) which reduce the levels of moisture within the internal cavity of the inhaler, thereby protecting the medicament powder within strip 506.
- the patient uses the inhaler by holding the device to his mouth, depressing lever 538, and inhaling through mouthpiece 535.
- Depression of lever 538 activates the internal mechanism of the inhaler, such that the lid 514 and base 510 sheets of coiled medicament blister strip 506 are separated at index wheel 541 by use of contracting wheel 542 and base wheel 543.
- a unit dose of powdered medicament within blister pocket 507 is released and may be inhaled by the patient through exit port 533 and mouthpiece 535.
- FIG 7 shows a top perspective of a container storage system for storing a dry powder inhaler or cartridge refill therefor according to the present invention.
- the container storage system 650 includes a package or wrapping 652 that employs multi-layers of material 970, 972, 974. (See Figure 10.)
- the package 652 further includes fin seams 654, 656 which are disposed along two parallel side edges of the package and along a single longitudinal edge of the package 652.
- the package 652 comprises a desiccant material, or alternatively is lined, coated or impregnated with a desiccant material.
- the number and type of fin seams 654, 656 are not limited to the types shown in the drawings.
- the package 652 can include additional seams or significantly fewer seams such as a continuous single seam.
- the orientation of the seams 654, 656 is not limited to the orientation shown in the drawings.
- the orientation of the seams 654, 656 is typically a function of the sealing device and such seams may be oriented in a manner which substantially increases manufacturing efficiency.
- the longitudinal seam 654 may be formed first by heat sealing and the two end seams 656 may then be formed by heat sealing to close the package.
- Other types of seams include, but are not limited to, gusset type seams which include excess material which provides expansibility, stitched type seams, or mechanically crimped seams, and other like structures.
- the container storage system includes a dry powder inhaler 820 (see Figure 9). While the preferred inhaler is a dry powder inhaler 820, other dry powder inhalers (such as that described in Figure 6) are not beyond the scope of the present invention.
- FIG 8 shows a side perspective of the container storage system of Figure 7.
- the fin seams 654 and 656 in Figure 7 are formed by a conventional heat sealing device which mechanically crimps sides of the package 750 together while simultaneously providing heat to the sides 654, 656/756 ( Figures 7 and 8).
- the heat sealing device typically has electrical heater elements shaped to produce the pattern of the fin seams 654, 656/756 where the fin seams include multiple ridges 658/758.
- the sealing mechanism of the container storage system 650/750 of the present invention is not limited to heat sealing devices.
- Other sealing devices include, but are not limited to, glue sealing machines, sonic welding machines, electron beam radiation machines, and other like sealing devices.
- the package 750 preferably has a substantially rectangular configuration with a substantially elliptical cross section, however, other shapes of the package 750 are not beyond the scope of the present invention. Other shapes include, but are not limited to circular, square, triangular, trapezoidal, pentagonal, hexagonal, octagonal, and other like shapes.
- the shape of the package 750 is preferably a function of the shape of the enclosed medicament powder container 34 as well as the amount and type of storage space since the package 752 is made from flexible materials as will be described in further detail below.
- Figure 9 shows a cut-away bottom perspective of the package for storing a dry powder inhaler according to the present invention.
- the package 852 provides an enclosed volume 860 in which the inhaler 820 is disposed therein.
- the size of the enclosed volume 860 can be adjusted according to the size of the inhaler 820 and related parts thereto.
- the enclosed volume 860 is of a size which permits relative ease of closing respective sides and layers 852, 26 and 28 without substantial stretching of the package 852.
- the enclosed volume 860 may be substantially evacuated prior to formation of the fin seams 858, 854 (not shown) to substantially reduce any water vapour being present in the enclosed volume 860.
- the enclosed volume 860 may be evacuated to such a degree that the enclosed volume 860 is a vacuum region around the medicament inhaler 820. While the enclosed volume 860, may remain constant, its relative shape may change according to shifting of the inhaler 820 disposed within the enclosed volume 860.
- a porous container of moisture absorbing material 862 lays adjacent to the mouthpiece 835 in a loose or free flowing manner.
- the moisture absorbing material 862 can be secured to the inside of the flexible package.
- the moisture absorbing container 862 may be attached to a bracket structure such as a ring which is fastened to the inhaler 820.
- the moisture absorbing material may be attached to the external surface of the mouthpiece 835 by a fastening device such as a rubber band 863.
- the fastening device 863 is preferably a removable elastic mechanism such as a rubber band.
- Other fastening devices include, but are not limited to, adhesives, adhesive tapes, shrink-wrap plastic, fasteners such as screws, nails, or rivets, compartments which are part of the mouthpiece housing 46, and other like attachment devices.
- a plurality of beads of material comprising a desiccant may be placed within the enclosed space 860.
- other carriers comprised of a desiccant material may be enclosed within space 860 to absorb excess moisture from the enclosure.
- Figure 10 is a cross-sectional view of the package for storing a dry powder inhaler according to the present invention.
- the amorphous shape of the enclosed volume 960 is attributed to the flexible materials which make up the layers 970, 972, 974 of the package 952.
- the enclosed volume 960 can be varied in size such that it substantially conforms to the shape of the inhaler and any related parts thereto or such that the enclosed volume 960 is larger than the inhaler 820, as shown in Figure 9.
- the enclosed volume is of a size which is substantially equivalent with the surface area of the inhaler 820 and related parts, the layers 970, 972, and 974 of material substantially conform to the shape of the inhaler and related parts.
- the package is preferably placed in a separate, more rigid container, such as a paperboard or cardboard box (not shown) typically used in the pharmaceutical industry.
- a separate, more rigid container such as a paperboard or cardboard box (not shown) typically used in the pharmaceutical industry.
- the package may expand during storage due to slow leakage of volatiles from the plastics constituting the body of the inhaler. In this situation, the shape of the package may conform to some extent to the internal shape of the rigid container if the volume of the rigid container is just slightly larger than the expanded volume of the flexible package.
- the flexible packaging material can be any material which is impervious to or substantially impervious to moisture.
- the packaging material is preferably permeable to volatiles which may escape from the plastics forming the body of the inhaler and/or the medicament carrier, by diffusion or otherwise, thereby preventing a build-up in pressure.
- the flexible packaging material preferably comprises a non- thermoplastic substrate (such as a metal foil) and a heat sealable layer disposed thereon, and an additional protective layer, such as a polymer film of polyester.
- the heat sealable layer is usually disposed on the inner surface of the assembled package.
- the additional protective layer is usually disposed on the surface opposite the heat sealable layer.
- An example of a particularly useful foil laminate is a polyester film adhesively laminated to aluminium foil adhesively laminated to lonomer (SURLYNTM) film, for example, 12 ⁇ polyester/9 ⁇ aluminum/50 ⁇ ionomer film supplied by Lawson Mardon Singen (LMS).
- SURLYNTM glass adhesively laminated to lonomer
- LMS Lawson Mardon Singen
- thicker metal films such as 20 to 25 ⁇ , may be used.
- the substrate is preferably formed from aluminium foil.
- other metals for the substrate include, but are not limited to, tin, iron, zinc, or magnesium formed on a sheet by vacuum deposition or sputtering and a carboxyl group-containing polyolefin layer formed on the metal layer by lamination.
- the heat sealable layer can be formed from any thermoplastic or thermosetting material such as an ionomer resin, polyolefin, or cycloolefin copolymer.
- lonomer resins typically include ionically cross- linked ethylene-methacrylic acid and ethylene acrylic acid copolymers. Properties which distinguish these ionomers resins from other polyolefin heat-sealed polymers are high clarity, high impact resistance, low haze in lamination, tear resistance, abrasion resistance, solid state toughness, and moisture imperviousness.
- the heat sealable layer is made out of SURLYNTM (an ionomer resin) or a form of polyethylene to provide sufficient heat sealing properties.
- the outer protective layer if present, can be formed of any material as long as the final laminate has the requisite properties.
- the protective layer e.g., polyester
- the substrate layer in turn is adhesively laminated to the heat sealable layer (e.g., the ionomer film or SURLYNTM (an ionomer resin)
- Preferred exemplary thicknesses of the three layers include a protective layer 1 to 40, preferably 4 to 30, more preferably 10 to 23 microns, and most preferably 12 microns; a substrate layer of 1 to 100, preferably 3 to 70, more preferably 5 to 50 microns, more preferably 6 to 20 microns, and most preferably 9 microns.
- preferred exemplary thicknesses include thicknesses of 1 to 100, preferably 5 to 70, more preferably 10 to 60, more preferably 20 to 55 microns, and most preferably 50 microns.
- Adhesives may be used to join the respective layers of materials together.
- the adhesive layers are typically substantially smaller in thickness relative to the thickness of the substrate, heat sealable and/or protective layers which they bond.
- the number, size, and shape of the layers are not limited to those layers shown in the drawings. Any number of layers with relative areas of any size and predetermined thicknesses may be used so long as the flexible package forms an enclosed volume which substantially prevents ingression of water vapour and particulate matter into the enclosed volume while permitting egression out of the enclosed volume of any volatile released from the plastics used in the body of the inhaler or the medicament carrier.
- the size, shape, and number of layers of the package are typically a function of the size and contents of the inhaler and/or medicament carrier.
- the package is believed to operate similarly to a virtual one-way valve due to the composition of the layers and due to the transmission rate of water vapour molecules into, the enclosed volume relative to the transmission rate of gas molecules of a plastic volatile, such as formaldehyde, out of the enclosed volume.
- the package permits the volatile to diffuse out of the enclosed volume while substantially preventing water vapour and other particulate matter from entering the enclosed volume. Excess or leakage of the volatile is permitted to egress from the package.
- the virtual one-way valve function of the package prevents or minimizes the chance of any sudden ruptures or prevents or minimizes unexpected expulsion of the plastic volatile during opening of the package.
- the moisture absorbing material is preferably a silica gel desiccant sachet.
- Other vapour or moisture absorbing materials include desiccants made from inorganic materials such a zeolites and aluminas.
- Such inorganic materials of vapour or moisture absorbing materials have high water absorption capacities and favourable water absorption isotherm shapes. The water absorption capacity of such materials typically varies from 20 to 50 weight percent.
- the absorbing material is a MINIPAX ® supplied by Multisorb Technologies in the United States and Silgelac in Europe (silica gel packaged inside TYVEK ® , which is a nylon mesh bonded with a microporous polyurethane).
- exemplary moisture absorbing materials include, but are not limited to, alumina, bauxite, anhydrous, calcium sulphate, water-absorbing clay, activated bentonite clay, a molecular sieve, or other like materials which optionally include a moisture sensitive colour indicator such as cobalt chloride to indicate when the desiccant is no longer operable. While in the preferred embodiment of the present invention, the package is designed to substantially prevent ingression of water vapour and particulate matter into the enclosed volume, the moisture absorbing material is placed within the enclosed volume in order to absorb any residual moisture present in the atmosphere or on the external surface of the pressurized container or mouthpiece or a combination thereof, prior to sealing the package.
- the desiccant should be present in an amount sufficient to absorb any residual moisture inside the package. When silica gel is used, 1g to 10g of silica gel is sufficient for a typical dry powder inhaler. Moreover, the desiccant should be present in an amount sufficient to absorb any moisture that possibly ingresses from the external environment. It is also possible to place the desiccant inside the container, either loose in the canister or as part of an assembly attached to the canister.
- Appropriate medicaments may thus be selected from, for example, analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate (eg s the sodium salt), ketotifen or nedocromil (eg as the sodium salt); antiinfectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g., methapyrilene; anti- inflammatories, e.g., beclomethasone (eg as the dipropionate ester), fluticasone (eg as the propionate ester), flunisolide, budesonide, rofleponide, mometasone eg as
- ⁇ integrin inhibitors eg (2S)-3-[4-( ⁇ [4- (aminocarbonyl)-1-piperidinyl]carbonyl ⁇ oxy)phenyl]-2-[((2S)-4-methyl-2- ⁇ [2-(2- methylphenoxy) acetyl]amino ⁇ pentanoyl)amino] propanoic acid (e.g as free acid or potassium salt), diuretics, e.g., amiloride; anticholinergics, e.g., ipratropium (eg as bromide), tiotropium, atropine or oxitropium; hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines, e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; therapeutic proteins and peptides, e.g., insulin or glu
- the medicaments may be used in the form of salts, (e.g., as alkali metal or amine salts or as acid addition salts) or as esters (e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimise the activity and/or stability of the medicament.
- salts e.g., as alkali metal or amine salts or as acid addition salts
- esters e.g., lower alkyl esters
- solvates e.g., hydrates
- Preferred medicaments are selected from albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof, e.g., the sulphate of albuterol and the xinafoate of salmeterol.
- Medicaments can also be delivered in combinations.
- Preferred formulations containing combinations of active ingredients contain salbutamol (e.g., as the free base or the sulphate salt) or salmeterol (e.g., as the xinafoate salt) or formoterol (eg as the fumarate salt) in combination with an antiinflammatory steroid such as a beclomethasone ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate) or budesonide.
- a particularly preferred combination is a combination of fluticasone propionate and salmeterol, or a salt thereof (particularly the xinafoate salt).
- a further combination of particular interest is budesonide and formoterol (e.g. as the fumarate salt).
- any of the parts of the medicament container used therewith which contact the medicament may be coated with materials such as fluoropolymer materials which reduce the tendency of medicament to adhere thereto.
- Suitable fluoropolymers include polytetrafluoroethylene (PTFE) and fluoroethylene propylene (FEP).
- PTFE polytetrafluoroethylene
- FEP fluoroethylene propylene
- Any movable parts may also have coatings applied thereto which enhance their desired movement characteristics. Frictional coatings may therefore be applied to enhance frictional contact and lubricants used to reduce frictional contact as necessary.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Mechanical Engineering (AREA)
- Biophysics (AREA)
- Packages (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Laminated Bodies (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Confectionery (AREA)
- Valve Device For Special Equipments (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60126609T DE60126609T3 (en) | 2000-06-21 | 2001-06-05 | CONTAINER FOR POWDERY MEDICAMENTS |
JP2002503623A JP2003535782A (en) | 2000-06-21 | 2001-06-05 | Container for pharmaceutical powder |
MXPA02012680A MXPA02012680A (en) | 2000-06-21 | 2001-06-05 | Container for medicament powder. |
CA002411109A CA2411109A1 (en) | 2000-06-21 | 2001-06-05 | Container for medicament powder |
AU2001274086A AU2001274086A1 (en) | 2000-06-21 | 2001-06-05 | Container for medicament powder |
EP01940550A EP1292510B2 (en) | 2000-06-21 | 2001-06-05 | Container for medicament powder |
BR0111252-0A BR0111252A (en) | 2000-06-21 | 2001-06-05 | Medicine powder container, method of reducing water ingress into a medicine powder, packaging for storing a medicine powder container, method of storing a medicine powder container, packed container, and powder medicine dispenser packed |
US10/276,932 US7828150B2 (en) | 2000-06-21 | 2001-06-05 | Container for medicament powder |
US11/427,370 US20060249419A1 (en) | 2000-06-21 | 2006-06-29 | Container for Medicament Powder |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0015043.3A GB0015043D0 (en) | 2000-06-21 | 2000-06-21 | Medicament dispenser |
GB0015043.3 | 2000-06-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/427,370 Continuation US20060249419A1 (en) | 2000-06-21 | 2006-06-29 | Container for Medicament Powder |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001098174A1 true WO2001098174A1 (en) | 2001-12-27 |
Family
ID=9894007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/006303 WO2001098174A1 (en) | 2000-06-21 | 2001-06-05 | Container for medicament powder |
Country Status (14)
Country | Link |
---|---|
US (2) | US7828150B2 (en) |
EP (2) | EP1292510B2 (en) |
JP (1) | JP2003535782A (en) |
CN (1) | CN1437551A (en) |
AT (1) | ATE353834T1 (en) |
AU (1) | AU2001274086A1 (en) |
BR (1) | BR0111252A (en) |
CA (1) | CA2411109A1 (en) |
DE (1) | DE60126609T3 (en) |
ES (1) | ES2282261T3 (en) |
GB (1) | GB0015043D0 (en) |
MX (1) | MXPA02012680A (en) |
WO (1) | WO2001098174A1 (en) |
ZA (1) | ZA200208212B (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1241110A1 (en) * | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Dispensing unit for oxygen-sensitive drugs |
WO2003055547A1 (en) * | 2001-12-22 | 2003-07-10 | Glaxo Group Limited | Medicament dispenser |
WO2004067069A2 (en) * | 2003-01-22 | 2004-08-12 | Valois Sas | Dose strip and inhaler comprising one such strip |
WO2004105727A2 (en) * | 2003-05-28 | 2004-12-09 | Aventis Pharma Limited | Stabilized pharmaceutical product |
WO2009103336A1 (en) * | 2008-02-20 | 2009-08-27 | Boehringer Ingelheim International Gmbh | Powder inhalers |
EP2098249A1 (en) * | 2008-03-05 | 2009-09-09 | Rivopharm SA | Nicorandil carriers with enhanced stability |
US7854225B2 (en) | 2002-11-02 | 2010-12-21 | Glaxo Group Limited | Blister package for inhalable medicament |
US7879833B2 (en) | 2002-12-12 | 2011-02-01 | Nycomed Gmbh | Combination medicament |
US7947744B2 (en) | 2003-07-08 | 2011-05-24 | Nycomed Gmbh | Stable pharmaceutical products |
WO2012028663A1 (en) | 2010-08-31 | 2012-03-08 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
WO2012028662A1 (en) | 2010-08-31 | 2012-03-08 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
WO2012038414A1 (en) * | 2010-09-21 | 2012-03-29 | Biogaia Ab | Product including lactic acid bacteria and a desiccant |
US8371292B2 (en) | 2003-09-16 | 2013-02-12 | Nycomed Gmbh | Use of ciclesonide for the treatment of respiratory diseases |
US8919342B2 (en) | 2007-08-01 | 2014-12-30 | Boehringer Ingelheim International Gmbh | Inhaler |
US8978645B2 (en) | 2005-04-04 | 2015-03-17 | Qingtang Chen | Dry powder aerosolized inhaler |
US9125998B2 (en) | 2008-01-24 | 2015-09-08 | Vectura Delivery Devices Limited | Inhaler |
EP2145758B2 (en) † | 2008-07-14 | 2017-06-07 | 3A Technology & Management AG | Packaging and packaging unit |
US11090294B2 (en) | 2009-12-01 | 2021-08-17 | Glaxo Group Limited | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
US11116721B2 (en) | 2009-02-26 | 2021-09-14 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
SE0101825D0 (en) * | 2001-05-22 | 2001-05-22 | Astrazeneca Ab | An inhalation device |
NZ532673A (en) * | 2001-11-17 | 2008-07-31 | Aventis Pharma Ltd | Package comprising a medicament, a component that gradually releases a gaseous substance and an adsorbent material |
US7258118B2 (en) | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
CA2479751C (en) | 2002-03-20 | 2008-06-03 | Trent Poole | Inhalation apparatus |
US20030235538A1 (en) * | 2002-04-09 | 2003-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for the administration of an anticholinergic by inhalation |
MXPA04010990A (en) * | 2002-05-07 | 2005-02-14 | Nektar Therapeutics | Capsules for dry powder inhalers and methods of making and using same. |
US7025205B2 (en) * | 2002-06-26 | 2006-04-11 | Aventis Pharma Limited | Method and packaging for pressurized containers |
PT1616549E (en) * | 2003-04-23 | 2012-11-12 | Otsuka Pharma Co Ltd | Drug solution filling plastic ampoule and process for producing the same |
SE0303570L (en) | 2003-12-03 | 2005-06-04 | Microdrug Ag | Moisture-sensitive medical product |
SE0303569L (en) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | DPI for delivery of moisture-sensitive drugs |
SE0303270L (en) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Method of administration of tiotropium |
SE0303571D0 (en) * | 2003-12-03 | 2003-12-22 | Microdrug Ag | Medical product for moisture-sensitive drugs |
SE0303269L (en) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Medical product |
FR2864944B1 (en) * | 2004-01-14 | 2006-03-31 | Valois Sas | STRIP OF BLISTERS FOR INHALER. |
SE530006C2 (en) * | 2004-06-18 | 2008-02-05 | Mederio Ag | Inhaler using tub |
SE0401654D0 (en) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | A support structure for a drug |
ES2385934T3 (en) | 2004-08-20 | 2012-08-03 | Mannkind Corporation | CATALYSIS OF THE SYNTHESIS OF DICETOPIPERAZINA. |
KR101644250B1 (en) | 2004-08-23 | 2016-07-29 | 맨카인드 코포레이션 | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
EP1827541B1 (en) * | 2004-10-21 | 2013-05-29 | Boehringer Ingelheim International GmbH | Blister for inhalers |
FR2877925B1 (en) * | 2004-11-16 | 2008-09-19 | Valois Sas | DEVICE FOR DISPENSING FLUID PRODUCT. |
GB0426780D0 (en) * | 2004-12-07 | 2005-01-12 | 3M Innovative Properties Co | Pressurized inhalation devices |
FR2881119B1 (en) * | 2005-01-25 | 2010-07-30 | Valois Sas | DEVICE FOR DISPENSING FLUID PRODUCT. |
GB2425115A (en) * | 2005-04-15 | 2006-10-18 | Vectura Group Plc | Blister pack |
JP4659523B2 (en) * | 2005-04-26 | 2011-03-30 | 共同印刷株式会社 | Blister film and blister packaging container |
TWI274641B (en) * | 2005-08-30 | 2007-03-01 | Rexon Ind Corp Ltd | Cutting machine |
DK1928423T3 (en) | 2005-09-14 | 2016-02-29 | Mannkind Corp | A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces |
US20070114237A1 (en) * | 2005-11-23 | 2007-05-24 | Canegallo Pirottavio | System and method to dispense single capsular bodies |
AU2007210177C1 (en) | 2006-01-31 | 2012-11-01 | Oriel Therapeutics, Inc. | Dry powder inhalers having spiral travel paths, unit dose microcartridges with dry powder, related devices and methods |
US8039431B2 (en) | 2006-02-22 | 2011-10-18 | Mannkind Corporation | Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
WO2008139523A1 (en) * | 2007-04-27 | 2008-11-20 | Daiwa Can Company | Polyester resin container with break part and process for producing the same |
US8881332B2 (en) * | 2007-08-17 | 2014-11-11 | Lise W. Noble | Toothbrush system utilizing oral care capsule |
GB0800459D0 (en) * | 2008-01-11 | 2008-02-20 | Innovata Biomed Ltd | Improvements in or relating to inhalers |
US20090235929A1 (en) * | 2008-03-19 | 2009-09-24 | Marc Egen | Powder inhalers |
DE102008018629A1 (en) * | 2008-04-11 | 2009-10-15 | Alcan Technology & Management Ag | Packaging film section, packaging film, packaging and packaging product unit |
IL191190A0 (en) * | 2008-05-01 | 2009-08-03 | Dan Adler | Dry powder inhaler |
US20090295108A1 (en) * | 2008-05-22 | 2009-12-03 | Albert Hisayuki Oku | Mobile Ball Hopper and Sport Bag Carrier |
AU2009257311B2 (en) | 2008-06-13 | 2014-12-04 | Mannkind Corporation | A dry powder inhaler and system for drug delivery |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
TWI532497B (en) | 2008-08-11 | 2016-05-11 | 曼凱公司 | Use of ultrarapid acting insulin |
US8919341B2 (en) * | 2008-12-03 | 2014-12-30 | Boehringer Ingelheim International Gmbh | Inhaler |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
KR100896958B1 (en) | 2009-02-12 | 2009-05-12 | 주식회사 제알코 | Packaging structure of medical supplies and packing method thereof |
JP5667095B2 (en) | 2009-03-11 | 2015-02-12 | マンカインド コーポレイション | Apparatus, system and method for measuring inhaler resistance |
CA2764505C (en) | 2009-06-12 | 2018-09-25 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
DK2453953T3 (en) * | 2009-07-14 | 2018-08-06 | Sanofi Aventis Deutschland | Medication container with a flexible inner layer and a rigid outer layer |
WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
TR200908847A2 (en) | 2009-11-23 | 2011-06-21 | Bi̇lgi̇ç Mahmut | Blister packaging carrying medicines in dry powder form. |
RU2571331C1 (en) | 2010-06-21 | 2015-12-20 | Маннкайнд Корпорейшн | Systems and methods for dry powder drug delivery |
JP5936542B2 (en) * | 2010-09-01 | 2016-06-22 | アステラス製薬株式会社 | Package |
US9101305B2 (en) * | 2011-03-09 | 2015-08-11 | Medtronic Minimed, Inc. | Glucose sensor product and related manufacturing and packaging methods |
CN105667994B (en) | 2011-04-01 | 2018-04-06 | 曼金德公司 | Blister package for pharmaceutical kit |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
CA2852536A1 (en) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Methods and compositions for treating pain |
HUE060421T2 (en) | 2012-01-25 | 2023-02-28 | Chiesi Farm Spa | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation |
USD694644S1 (en) | 2012-03-28 | 2013-12-03 | Aventisub Ii Inc. | Clamshell package having blisters |
US8899419B2 (en) | 2012-03-28 | 2014-12-02 | Aventisub Ii Inc. | Package with break-away clamshell |
USD693695S1 (en) | 2012-03-28 | 2013-11-19 | Aventisub Ii Inc. | Package for product |
USD695625S1 (en) | 2012-03-28 | 2013-12-17 | Aventisub Ii Inc. | Package for product |
USD697813S1 (en) | 2012-03-28 | 2014-01-21 | Aventisub Ii Inc. | Clamshell having blisters received therein |
USD687313S1 (en) | 2012-03-28 | 2013-08-06 | Aventisub Ii Inc. | A-shaped blister card |
US8919559B2 (en) | 2012-03-28 | 2014-12-30 | Aventisub Ii Inc. | Package with break-away clamshell |
WO2013176635A1 (en) | 2012-05-25 | 2013-11-28 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhaler device having an improved guide gear |
US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
ES2754388T3 (en) | 2013-03-15 | 2020-04-17 | Mannkind Corp | Compositions and methods of microcrystalline dicetopiperazine |
ES2699986T3 (en) | 2013-07-11 | 2019-02-13 | Chiesi Farm Spa | Formulation of dry powder comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
EP3030294B1 (en) | 2013-08-05 | 2020-10-07 | MannKind Corporation | Insufflation apparatus |
DK3105521T3 (en) | 2014-01-23 | 2020-04-06 | Stasis Lmps Ltd | FLEXIBLE PANEL AND SEALABLE POSITION WITH SORPING AGENT |
US20170113864A1 (en) * | 2014-03-27 | 2017-04-27 | Avantor Performance Materials, Inc. | Package system and method for inhibiting moisture entry |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US9554992B2 (en) | 2014-06-09 | 2017-01-31 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic |
KR101481733B1 (en) * | 2014-06-30 | 2015-01-12 | 주식회사 선양 | Dehumidifying and deodorizing functional compound having a three-layer packaging film and its manufacturing method |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
JP6942126B2 (en) | 2015-11-16 | 2021-09-29 | キエージ・フアルマチエウテイチ・エツセ・ピ・ア | Method for Producing Dry Powder Formulation Containing Anticholinergic Agent, Corticosteroid and β-Adrenaline Agent |
ES2895687T3 (en) | 2015-11-16 | 2022-02-22 | Chiesi Farm Spa | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
JP6976970B2 (en) * | 2016-07-07 | 2021-12-08 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | Nicotine inhaler system |
CN108622469B (en) * | 2017-03-24 | 2023-08-15 | 李和伟 | Crawler-type ware of dosing of independent packing |
PL3621590T3 (en) | 2017-05-11 | 2022-01-17 | Chiesi Farmaceutici S.P.A. | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
ES2882153T3 (en) | 2017-05-11 | 2021-12-01 | Chiesi Farm Spa | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid, and a beta-adrenergic |
GB201710653D0 (en) | 2017-07-03 | 2017-08-16 | One Hundred Flowers Ltd | Inhaler |
US20190076607A1 (en) * | 2017-09-13 | 2019-03-14 | Lupin Atlantis Holdings Sa | Inhaler and mesh for an inhaler |
US11896720B2 (en) * | 2017-09-26 | 2024-02-13 | Captek Softgel International | Orally available articles containing at least one stabilized supplement therein |
CL2017002724A1 (en) * | 2017-10-26 | 2018-07-13 | Univ Adolfo Ibanez | Device that allows humidity levels to be controlled inside a container |
CN113038931A (en) * | 2018-06-29 | 2021-06-25 | Csp技术公司 | Low odor or odorless absorber desiccant polymer |
CN110338465A (en) * | 2019-07-16 | 2019-10-18 | 深圳麦克韦尔科技有限公司 | Scavenging air valve and electronic atomization device |
WO2023117967A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
WO2023117985A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1069929A (en) * | 1964-05-01 | 1967-05-24 | Schuepbach Ag | Packaging material |
GB1073786A (en) * | 1964-03-26 | 1967-06-28 | Participations Et Procedes Ind | Containers incorporating dehydrating devices |
US3921805A (en) * | 1972-10-10 | 1975-11-25 | Newton L Compere | Rupturable blister pill package with safety backing |
WO1989001348A1 (en) | 1987-08-20 | 1989-02-23 | Teijin Limited | Powdery medicine applicator device |
EP0455463A1 (en) * | 1990-04-30 | 1991-11-06 | Riker Laboratories, Inc. | Packaging for microdoses of powdered medicament for inhalation |
US5394868A (en) | 1992-06-25 | 1995-03-07 | Schering Corporation | Inhalation device for powdered medicaments |
WO1996033108A1 (en) * | 1995-04-19 | 1996-10-24 | Capitol Vial, Inc. | Desiccant material included in a closed container |
US5687746A (en) | 1993-02-08 | 1997-11-18 | Advanced Therapeutic Products, Inc. | Dry powder delivery system |
US5740793A (en) | 1989-04-28 | 1998-04-21 | Astra Aktiebolag | Dry powder inhalation device with elongate carrier for power |
US5775320A (en) | 1991-07-02 | 1998-07-07 | Inhale Therapeutic Systems | Method and device for delivering aerosolized medicaments |
WO1999032180A1 (en) | 1997-12-22 | 1999-07-01 | Astrazeneca Ab | Inhalation device |
US6029663A (en) * | 1995-04-24 | 2000-02-29 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
US6050400A (en) * | 1994-06-10 | 2000-04-18 | Smithkline Beecham Plc | Package |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US577532A (en) * | 1897-02-23 | Annunciator | ||
US2524162A (en) | 1945-02-27 | 1950-10-03 | Chavannes Marc Alfred | Desiccant packaging |
US2517482A (en) * | 1949-04-09 | 1950-08-01 | Sharp & Dohme Inc | Inhaler |
US3333683A (en) | 1966-02-17 | 1967-08-01 | Anaconda Aluminum Co | Cigarette package |
US3371825A (en) | 1966-05-12 | 1968-03-05 | Multiform Desiccant Products I | Sorptive getter for pressure discharge dispensers |
NL6900448A (en) | 1968-12-05 | 1970-06-09 | ||
FR2086553A5 (en) | 1970-04-01 | 1971-12-31 | Oreal | |
US3704806A (en) | 1971-01-06 | 1972-12-05 | Le T Im Lensoveta | Dehumidifying composition and a method for preparing the same |
US3809223A (en) | 1971-08-27 | 1974-05-07 | Crown Zellerbach Corp | Protected lumber package and method of making same |
US3788322A (en) | 1972-12-27 | 1974-01-29 | Alza Corp | Drug delivery device with means for maintaining device in environment of use |
US3797492A (en) | 1972-12-27 | 1974-03-19 | Alza Corp | Device for dispensing product with directional guidance member |
US4135622A (en) | 1973-03-28 | 1979-01-23 | American Cyanamid Company | Packaged, desiccated surgical elements |
SE382606B (en) | 1975-05-06 | 1976-02-09 | Svenska Dental Instrument Ab | STERILE PACKAGING |
CA1097233A (en) * | 1977-07-20 | 1981-03-10 | George K. E. Gregory | Packages |
US4274403A (en) * | 1979-08-29 | 1981-06-23 | Struve Roger L | Inhaler |
DE3110947A1 (en) * | 1981-03-20 | 1982-10-07 | Dieter Gräßlin Feinwerktechnik, 7742 St Georgen | "PROGRAM INPUT AND / OR TIME SETTING DEVICE" |
US4702963A (en) | 1981-04-03 | 1987-10-27 | Optical Coating Laboratory, Inc. | Flexible polymer film with vapor impermeable coating |
US4429792A (en) * | 1981-09-11 | 1984-02-07 | Medication Services, Inc. | Medication-dispensing card |
US4447565A (en) | 1981-12-07 | 1984-05-08 | The United States Of America As Represented By The United States Department Of Energy | Method and composition for molding low density desiccant syntactic foam articles |
US4363841A (en) | 1981-12-28 | 1982-12-14 | Champion International Corporation | Laminated packaging material |
US4447585A (en) * | 1982-03-04 | 1984-05-08 | The Goodyear Tire & Rubber Company | Polymer bound aryl substituted crown ethers |
US4449632A (en) | 1982-12-15 | 1984-05-22 | Marusiak Jr Frank | Tamper-proof package and method |
US4570820A (en) | 1983-01-18 | 1986-02-18 | Creative Products Resource Associates, Ltd. | Resealable dispensing container for folded towels |
ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
US4509196A (en) | 1983-06-30 | 1985-04-02 | Arvey Corporation | Tamper-indicating self-sealing pouch |
US4664256A (en) | 1983-09-06 | 1987-05-12 | Farmaceutisk Laboratorium Ferring A/S | Packaged stable enema solution or suspension containing 5-aminosalicyclic acid |
US4655229A (en) | 1984-01-30 | 1987-04-07 | R. J. Reynolds Tobacco Company | Flavor delivery system |
US5743398A (en) | 1984-05-22 | 1998-04-28 | Southpac Trust International, Inc. | Floral wrapper utilizing a breathable packaging material |
US6022627A (en) | 1993-08-17 | 2000-02-08 | Southpac Trust International, Inc. | Floral wrapper utilizing a breathable packaging material |
SE465417B (en) | 1984-06-21 | 1991-09-09 | Toyo Seikan Kaisha Ltd | PLASTIC CONTAINERS MADE OF LAMINATE INCLUDING A GAS BARRIER LAYER |
US4665229A (en) * | 1985-02-14 | 1987-05-12 | Ashland Oil, Inc. | Preparation of hydroxy alkyl amide thio ether compounds from bicyclic amide acetal and thiol |
US4645073A (en) | 1985-04-02 | 1987-02-24 | Survival Technology, Inc. | Anti-contamination hazardous material package |
DE3524846A1 (en) | 1985-07-12 | 1987-01-15 | Hoechst Ag | PACKING FOR DRY RESISTANT MATERIAL |
US4938238A (en) | 1985-08-26 | 1990-07-03 | R. J. Reynolds Tobacco Company | Smoking article with improved wrapper |
US5073599A (en) | 1985-11-29 | 1991-12-17 | American National Can Company | Films using blends of polypropylene and polyisobutylene |
DE8605885U1 (en) † | 1986-03-04 | 1986-04-17 | Eurim-Pharm Arzneimittel GmbH, 8235 Piding | Child lock for blister strips |
DE3610345C2 (en) | 1986-03-27 | 1998-07-09 | Rathor Ag | Device for producing polyurethane assembly foam |
US4720423A (en) | 1986-08-25 | 1988-01-19 | Minnesota Mining And Manufacturing Company | Package opening system |
US4757919A (en) | 1986-09-23 | 1988-07-19 | The Coca-Cola Company | Shut-off valve for juice dispensing system |
US4718553A (en) | 1987-02-11 | 1988-01-12 | Ivy Hill Corporation | Tamper-evident packaging, method of making same, and intermediate therein |
DE3715938A1 (en) | 1987-05-13 | 1988-11-24 | Boehringer Mannheim Gmbh | CONTAINER FOR TEST STRIP |
US4815602A (en) | 1987-10-30 | 1989-03-28 | W.R. Grace & Co. | Vacuum skin package for closing two moisture impervious metallic sheets about a product |
US4802583A (en) | 1988-03-11 | 1989-02-07 | The Mead Corporation | Article container with overwrap |
US4811571A (en) | 1988-03-28 | 1989-03-14 | Thermo King Corporation | Refrigerant drier |
US4861632A (en) | 1988-04-19 | 1989-08-29 | Caggiano Michael A | Laminated bag |
US4907394A (en) | 1988-05-27 | 1990-03-13 | Unionpack Industrielle Lohnverpackuns-Gmbh & Co. | Method for producing a foil-container, apparatus for the implementation of the said method, and a foil-container produced according to the said method |
JP2592500B2 (en) | 1988-06-01 | 1997-03-19 | 三井石油化学工業株式会社 | Laminated film |
US5062569A (en) | 1988-08-01 | 1991-11-05 | Hekal Ihal M | Peelably sealed plastic packages and method of preparing same |
US4934524A (en) | 1988-09-19 | 1990-06-19 | Brown & Williamson Tobacco Corporation | Package for storing moisture laden articles |
US5186775A (en) | 1988-10-05 | 1993-02-16 | Cullen John S | Method of fabrication of a container for bulk material |
US4874090A (en) | 1988-10-24 | 1989-10-17 | American Sterilizer Company | Self-seal sterilization pouch |
GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
US5035935A (en) | 1989-01-19 | 1991-07-30 | Philip Morris Incorporated | Overwrap insert |
US5718355A (en) | 1989-02-03 | 1998-02-17 | Senetics, Inc. | Indicator device responsive to axial force for use with inhaler |
US4972953A (en) | 1989-06-14 | 1990-11-27 | Ivy Hill Corporation | Tamper-evident packaging, method of making same and intermediate therein |
GB8919131D0 (en) | 1989-08-23 | 1989-10-04 | Riker Laboratories Inc | Inhaler |
US5270305A (en) | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
GB8925707D0 (en) | 1989-11-14 | 1990-01-04 | Riker Laboratories Inc | Device |
US5201308A (en) | 1990-02-14 | 1993-04-13 | Newhouse Michael T | Powder inhaler |
US5113855A (en) | 1990-02-14 | 1992-05-19 | Newhouse Michael T | Powder inhaler |
US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
US5814337A (en) * | 1992-10-07 | 1998-09-29 | Beecham Group Plc | Pharmaceutical formulation |
DE4013799A1 (en) | 1990-04-28 | 1991-10-31 | Gaplast Gmbh | PLASTIC CONTAINER AND CONTAINER CLOSURE, ESPECIALLY FOR MEDICINAL PRODUCTS |
US5126123A (en) | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
US5304419A (en) | 1990-07-06 | 1994-04-19 | Alpha Fry Ltd | Moisture and particle getter for enclosures |
DE4027391A1 (en) | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | GAS-FREE INHALATION DEVICE |
US5042472A (en) * | 1990-10-15 | 1991-08-27 | Merck & Co., Inc. | Powder inhaler device |
US6119688A (en) | 1991-08-26 | 2000-09-19 | 3M Innovative Properties Company | Powder dispenser |
IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
US5916540A (en) | 1994-10-24 | 1999-06-29 | Glaxo Group Limited | Aerosol formulations containing P134A and/or P227 and particulate medicament |
GB9203761D0 (en) * | 1992-02-21 | 1992-04-08 | Innovata Biomed Ltd | Inhaler |
US5330047A (en) | 1992-04-27 | 1994-07-19 | Rhone-Poulenc Inc. | Packaging for agrichemicals |
CA2099940A1 (en) | 1992-07-06 | 1994-01-07 | Kenneth A. Thomas | Tear tape |
NZ255541A (en) * | 1992-09-09 | 1996-05-28 | Fisons Plc | Blister package for medicament-containing capsules with an aperture for dispensing the medicament; the package base has a sealing means to seal the capsule aperture |
GB2272162B (en) | 1992-11-06 | 1996-10-09 | Paul Richard Yerbury | Dust proof inhaler |
US5322161A (en) | 1992-11-30 | 1994-06-21 | United States Surgical Corporation | Clear package for bioabsorbable articles |
HU215510B (en) | 1992-12-18 | 1999-01-28 | Schering Corp. | Inhaler for powdered medications |
US5756171A (en) | 1992-12-22 | 1998-05-26 | Kabushiki Kaisha Hosokawa Yoko | Laminate film and method of producing the same |
GB9306703D0 (en) | 1993-03-31 | 1993-05-26 | Fisons Plc | Inhalation device |
AU695969B2 (en) | 1993-04-30 | 1998-08-27 | Minnesota Mining And Manufacturing Company | Seal configuration for aerosol canister |
JPH0796977A (en) | 1993-06-08 | 1995-04-11 | Ajinomoto Co Inc | Double packing material for easily oxidized substance |
US5451437A (en) | 1993-06-21 | 1995-09-19 | Minnesota Mining And Manufacturing Company | Method and article for protecting a container that holds a fluid |
JPH0733172A (en) * | 1993-07-08 | 1995-02-03 | Toppan Printing Co Ltd | Multi-layer plastic container |
US5524613A (en) | 1993-08-25 | 1996-06-11 | Habley Medical Technology Corporation | Controlled multi-pharmaceutical inhaler |
GB9404945D0 (en) * | 1994-03-15 | 1994-04-27 | Glaxo Group Ltd | Pharmaceutical composition |
GB9405249D0 (en) * | 1994-03-17 | 1994-04-27 | Smithkline Beecham Plc | Container |
US5472092A (en) | 1994-03-30 | 1995-12-05 | H. J. Heinz Company | Shrink wrapped package and method for its production |
US5820956A (en) | 1994-06-24 | 1998-10-13 | Mitsubishi Gas Chemical Company, Inc. | Multi-layer structural body |
JPH10505764A (en) | 1994-09-16 | 1998-06-09 | ラボラトワール、グラクソ、ウェルカム | Inhaler |
US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
US5551557A (en) | 1994-10-25 | 1996-09-03 | Convey, Inc. | Efficient method and apparatus for establishing shelf-life of getters utilized within sealed enclosures |
US5565164A (en) * | 1995-03-17 | 1996-10-15 | Limited Resources, Inc. | Method and apparatus for densifying a thermoplastic polymer |
RO119117B1 (en) | 1995-04-14 | 2004-04-30 | Glaxo Wellcome Inc. | Fixed dose inhaler for fluticasone propionate |
EE03997B1 (en) | 1995-04-14 | 2003-04-15 | Glaxo Wellcome Inc. | Albuterol metered dose inhaler |
US6194079B1 (en) † | 1995-04-19 | 2001-02-27 | Capitol Specialty Plastics, Inc. | Monolithic polymer composition having an absorbing material |
US6279736B1 (en) * | 1995-04-19 | 2001-08-28 | Capitol Specialty Plastics, Inc. | Barrier pack having an absorbing agent applied to the interior of the pack |
US5911937A (en) | 1995-04-19 | 1999-06-15 | Capitol Specialty Plastics, Inc. | Desiccant entrained polymer |
US5645051A (en) | 1995-04-21 | 1997-07-08 | Dura Pharmaceuticals, Inc. | Unit dose dry powder inhaler |
US5789044A (en) | 1996-01-24 | 1998-08-04 | Eastman Kodak Company | Zeolite molecular sieves for packaging structures |
GB2306169B (en) | 1995-10-13 | 2000-01-12 | Eastman Kodak Co | Zeolite molecular sieves for packaging structures |
US5833066A (en) | 1996-01-02 | 1998-11-10 | Inhalermate, Llc | Carrying case for oral and nasal inhalation devices with counting mechanism |
CZ212598A3 (en) | 1996-01-03 | 1998-11-11 | Glaxo Group Limited | Inhalation apparatus |
US5833093A (en) | 1996-03-04 | 1998-11-10 | Honaker; Denise | Protective cover for small spray dispensers and medicated inhalers |
US5773105A (en) | 1996-03-07 | 1998-06-30 | United Catalysts Inc. - Desiccants | Absorbent packet |
US5749496A (en) | 1996-06-19 | 1998-05-12 | Primary Delivery Systems, Inc. | Squeeze and rotate to lift captive cap dispenser |
US6112888A (en) * | 1996-06-28 | 2000-09-05 | W. R. Grace & Co.-Conn. | Non-reclosable packages containing desiccant matrix |
DE19633495A1 (en) | 1996-08-20 | 1998-02-26 | Sanner Friedr Gmbh Co Kg | Desiccant seal for container filled with moisture sensitive goods |
DE19646048C2 (en) | 1996-11-08 | 2003-05-28 | Michael Horstmann | Packaging for transdermal therapeutic systems |
SE9700944D0 (en) | 1997-03-14 | 1997-03-14 | Astra Ab | Powder inhales VI |
US5779122A (en) | 1997-05-05 | 1998-07-14 | Martinelli; Vincent | Asthma medication pouch |
US6093480A (en) | 1997-05-21 | 2000-07-25 | Tenneco Packaging | Stretch wrap films |
US6103280A (en) | 1997-09-20 | 2000-08-15 | Bass Public Limited Company | Self-cooling containers of beverage and foodstuffs |
US6617321B2 (en) * | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
US6039718A (en) | 1998-01-20 | 2000-03-21 | Bracco Research Usa | Multiple use universal connector |
US6019751A (en) | 1998-01-20 | 2000-02-01 | Bracco Research Usa | Universal connector and a medical container |
JPH11206850A (en) * | 1998-01-29 | 1999-08-03 | Dai Ichi Seiyaku Co Ltd | Drug packaging body |
US5896989A (en) | 1998-02-20 | 1999-04-27 | Bracco Research Usa | Flexible medical container packaging |
GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
US6207093B1 (en) | 1998-04-24 | 2001-03-27 | Fina Technology, Inc. | Compositions for improved orientation processing |
US6241132B1 (en) | 1998-05-13 | 2001-06-05 | The Testor Corporation | Fluid dispensing apparatus with fitment spout and valve |
AU4204799A (en) † | 1998-06-04 | 1999-12-20 | Capitol Specialty Plastics, Inc. | Desiccant blended in a thermoplastic |
US6315112B1 (en) | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6119853A (en) | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6250468B1 (en) | 1999-02-10 | 2001-06-26 | Teepak Investments, Inc. | Easy to remove overwrap |
US6531197B2 (en) | 1999-04-26 | 2003-03-11 | Illinois Tool Works | Desiccant barrier container |
FR2793379B1 (en) | 1999-05-11 | 2001-07-06 | Kuhn Sa | ADAPTER FOR A TRACTOR HITCH BAR |
US6360929B1 (en) | 2000-07-17 | 2002-03-26 | Mccarthy Madeleine | Medicinal atomizing inhaler pouch/retainer |
FR2812620B1 (en) * | 2000-08-04 | 2002-12-27 | David Platre | REVERSIBLE SEALING DEVICE FOR CONTAINER |
US20040131805A1 (en) | 2002-06-20 | 2004-07-08 | Merical Rick L. | Films having a desiccant material incorporated therein and methods of use and manufacture |
US20060269708A1 (en) | 2002-06-20 | 2006-11-30 | Rick Merical | Films having a desiccant material incorporated therein and methods of use and manufacture |
US20030235664A1 (en) | 2002-06-20 | 2003-12-25 | Rick Merical | Films having a desiccant material incorporated therein and methods of use and manufacture |
SE0401654D0 (en) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | A support structure for a drug |
EP1827541B1 (en) | 2004-10-21 | 2013-05-29 | Boehringer Ingelheim International GmbH | Blister for inhalers |
-
2000
- 2000-06-21 GB GBGB0015043.3A patent/GB0015043D0/en not_active Ceased
-
2001
- 2001-06-05 ES ES01940550T patent/ES2282261T3/en not_active Expired - Lifetime
- 2001-06-05 MX MXPA02012680A patent/MXPA02012680A/en unknown
- 2001-06-05 CN CN01811527A patent/CN1437551A/en active Pending
- 2001-06-05 EP EP01940550A patent/EP1292510B2/en not_active Expired - Lifetime
- 2001-06-05 AT AT01940550T patent/ATE353834T1/en not_active IP Right Cessation
- 2001-06-05 CA CA002411109A patent/CA2411109A1/en not_active Abandoned
- 2001-06-05 JP JP2002503623A patent/JP2003535782A/en active Pending
- 2001-06-05 US US10/276,932 patent/US7828150B2/en not_active Expired - Lifetime
- 2001-06-05 DE DE60126609T patent/DE60126609T3/en not_active Expired - Lifetime
- 2001-06-05 AU AU2001274086A patent/AU2001274086A1/en not_active Abandoned
- 2001-06-05 WO PCT/EP2001/006303 patent/WO2001098174A1/en active IP Right Grant
- 2001-06-05 EP EP06075817A patent/EP1760008A1/en not_active Withdrawn
- 2001-06-05 BR BR0111252-0A patent/BR0111252A/en not_active IP Right Cessation
-
2002
- 2002-10-11 ZA ZA200208212A patent/ZA200208212B/en unknown
-
2006
- 2006-06-29 US US11/427,370 patent/US20060249419A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1073786A (en) * | 1964-03-26 | 1967-06-28 | Participations Et Procedes Ind | Containers incorporating dehydrating devices |
GB1069929A (en) * | 1964-05-01 | 1967-05-24 | Schuepbach Ag | Packaging material |
US3921805A (en) * | 1972-10-10 | 1975-11-25 | Newton L Compere | Rupturable blister pill package with safety backing |
WO1989001348A1 (en) | 1987-08-20 | 1989-02-23 | Teijin Limited | Powdery medicine applicator device |
US5740793A (en) | 1989-04-28 | 1998-04-21 | Astra Aktiebolag | Dry powder inhalation device with elongate carrier for power |
EP0455463A1 (en) * | 1990-04-30 | 1991-11-06 | Riker Laboratories, Inc. | Packaging for microdoses of powdered medicament for inhalation |
US5775320A (en) | 1991-07-02 | 1998-07-07 | Inhale Therapeutic Systems | Method and device for delivering aerosolized medicaments |
US5394868A (en) | 1992-06-25 | 1995-03-07 | Schering Corporation | Inhalation device for powdered medicaments |
US5687746A (en) | 1993-02-08 | 1997-11-18 | Advanced Therapeutic Products, Inc. | Dry powder delivery system |
US6050400A (en) * | 1994-06-10 | 2000-04-18 | Smithkline Beecham Plc | Package |
WO1996033108A1 (en) * | 1995-04-19 | 1996-10-24 | Capitol Vial, Inc. | Desiccant material included in a closed container |
US6029663A (en) * | 1995-04-24 | 2000-02-29 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
WO1999032180A1 (en) | 1997-12-22 | 1999-07-01 | Astrazeneca Ab | Inhalation device |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1241110A1 (en) * | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Dispensing unit for oxygen-sensitive drugs |
WO2003055547A1 (en) * | 2001-12-22 | 2003-07-10 | Glaxo Group Limited | Medicament dispenser |
US7854225B2 (en) | 2002-11-02 | 2010-12-21 | Glaxo Group Limited | Blister package for inhalable medicament |
US8258124B2 (en) | 2002-12-12 | 2012-09-04 | Nycomed Gmbh | Combination medicament |
US7879833B2 (en) | 2002-12-12 | 2011-02-01 | Nycomed Gmbh | Combination medicament |
WO2004067069A2 (en) * | 2003-01-22 | 2004-08-12 | Valois Sas | Dose strip and inhaler comprising one such strip |
WO2004067069A3 (en) * | 2003-01-22 | 2004-10-21 | Valois Sas | Dose strip and inhaler comprising one such strip |
CN100525852C (en) * | 2003-01-22 | 2009-08-12 | 瓦卢瓦有限合伙公司 | Dose strip and inhaler comprising one such strip |
WO2004105727A3 (en) * | 2003-05-28 | 2005-06-16 | Aventis Pharma Ltd | Stabilized pharmaceutical product |
US8029811B2 (en) | 2003-05-28 | 2011-10-04 | Nycomed Gmbh | Stabilized pharmaceutical product |
WO2004105727A2 (en) * | 2003-05-28 | 2004-12-09 | Aventis Pharma Limited | Stabilized pharmaceutical product |
US7736673B2 (en) | 2003-05-28 | 2010-06-15 | Nycomed Gmbh | Stabilized pharmaceutical product |
JP2007504277A (en) * | 2003-05-28 | 2007-03-01 | アベンティス・フアーマ・リミテッド | Stabilized pharmaceutical products |
US8163299B2 (en) | 2003-05-28 | 2012-04-24 | Nycomed Gmbh | Stabilized pharmaceutical product |
US8440210B2 (en) | 2003-05-28 | 2013-05-14 | Takeda Gmbh | Stabilized pharmaceutical product |
US7947744B2 (en) | 2003-07-08 | 2011-05-24 | Nycomed Gmbh | Stable pharmaceutical products |
US8288445B2 (en) | 2003-07-08 | 2012-10-16 | Nycomed Gmbh | Stable pharmaceutical products |
US8371292B2 (en) | 2003-09-16 | 2013-02-12 | Nycomed Gmbh | Use of ciclesonide for the treatment of respiratory diseases |
US8978645B2 (en) | 2005-04-04 | 2015-03-17 | Qingtang Chen | Dry powder aerosolized inhaler |
US8919342B2 (en) | 2007-08-01 | 2014-12-30 | Boehringer Ingelheim International Gmbh | Inhaler |
US9125998B2 (en) | 2008-01-24 | 2015-09-08 | Vectura Delivery Devices Limited | Inhaler |
WO2009103336A1 (en) * | 2008-02-20 | 2009-08-27 | Boehringer Ingelheim International Gmbh | Powder inhalers |
WO2009109596A1 (en) * | 2008-03-05 | 2009-09-11 | Rivopharm Sa | Nicorandil carriers with enhanced stability |
EP2098249A1 (en) * | 2008-03-05 | 2009-09-09 | Rivopharm SA | Nicorandil carriers with enhanced stability |
EA020134B1 (en) * | 2008-03-05 | 2014-08-29 | Ривофарм Са | Nicorandil carriers with enhanced stability |
EP2145758B2 (en) † | 2008-07-14 | 2017-06-07 | 3A Technology & Management AG | Packaging and packaging unit |
US11116721B2 (en) | 2009-02-26 | 2021-09-14 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
US11090294B2 (en) | 2009-12-01 | 2021-08-17 | Glaxo Group Limited | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
EP3461474A1 (en) * | 2010-08-31 | 2019-04-03 | GlaxoSmithKline Intellectual Property Development Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
WO2012028663A1 (en) | 2010-08-31 | 2012-03-08 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
EP2611423B1 (en) | 2010-08-31 | 2015-06-24 | GlaxoSmithKline Intellectual Property Development Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
EP2954888A1 (en) | 2010-08-31 | 2015-12-16 | GlaxoSmithKline Intellectual Property Development Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
WO2012028662A1 (en) | 2010-08-31 | 2012-03-08 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
EP2611422B1 (en) | 2010-08-31 | 2018-10-31 | GlaxoSmithKline Intellectual Property Development Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
AU2011298409B2 (en) * | 2010-08-31 | 2013-11-21 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
EP3461474B1 (en) | 2010-08-31 | 2020-11-11 | GlaxoSmithKline Intellectual Property Development Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
US20130156828A1 (en) * | 2010-08-31 | 2013-06-20 | Osama Ahmed Aswania | Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same |
WO2012038414A1 (en) * | 2010-09-21 | 2012-03-29 | Biogaia Ab | Product including lactic acid bacteria and a desiccant |
RU2578577C2 (en) * | 2010-09-21 | 2016-03-27 | Биогайа Аб | Products containing lactic acid bacteria, and a desiccant |
US9351512B2 (en) | 2010-09-21 | 2016-05-31 | Biogaia Ab | Active plastic material in oil |
US8785183B2 (en) | 2010-09-21 | 2014-07-22 | Biogaia Ab | Active plastic material in oil |
Also Published As
Publication number | Publication date |
---|---|
EP1760008A1 (en) | 2007-03-07 |
BR0111252A (en) | 2003-06-03 |
GB0015043D0 (en) | 2000-08-09 |
ES2282261T3 (en) | 2007-10-16 |
CN1437551A (en) | 2003-08-20 |
JP2003535782A (en) | 2003-12-02 |
AU2001274086A1 (en) | 2002-01-02 |
EP1292510B2 (en) | 2011-07-20 |
ZA200208212B (en) | 2003-07-17 |
EP1292510A1 (en) | 2003-03-19 |
EP1292510B1 (en) | 2007-02-14 |
CA2411109A1 (en) | 2001-12-27 |
MXPA02012680A (en) | 2003-04-25 |
DE60126609T2 (en) | 2007-10-31 |
US20060249419A1 (en) | 2006-11-09 |
DE60126609T3 (en) | 2012-01-26 |
US7828150B2 (en) | 2010-11-09 |
DE60126609D1 (en) | 2007-03-29 |
ATE353834T1 (en) | 2007-03-15 |
US20030140923A1 (en) | 2003-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7828150B2 (en) | Container for medicament powder | |
US20050039743A1 (en) | Medicament dispenser | |
US6119853A (en) | Method and package for storing a pressurized container containing a drug | |
US6352152B1 (en) | Method and package for storing a pressurized container containing a drug | |
US10376662B2 (en) | Dry powder inhalers | |
US6390291B1 (en) | Method and package for storing a pressurized container containing a drug | |
US6315112B1 (en) | Method and package for storing a pressurized container containing a drug | |
US20060032763A1 (en) | Method and package for storing a pressurized container containing a drug | |
WO2001097888A2 (en) | Method and package for storing a pressurized container containing a drug | |
US20040089561A1 (en) | Method and package for storing a pressurized container containing a drug | |
MXPA01005898A (en) | Method and package for storing a pressurized container containing a drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001940550 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/08212 Country of ref document: ZA Ref document number: 200208212 Country of ref document: ZA Ref document number: IN/PCT/2002/1277/KOL Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001274086 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10276932 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2411109 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/012680 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018115276 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001940550 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001940550 Country of ref document: EP |